

Index

a

abbreviated 510(k) 239, 240
 Abbreviated New Drug Application (ANDA) 123–124, 182
 acceptable daily intake (ADI) 148
 active pharmaceutical ingredient (API) 49, 51, 89, 245, 246, 252
 adverse event reporting 97, 223, 296
 advertising and promotion 297
 analytical methods 7, 77, 140, 152, 265
 anatomical therapeutic chemical (ATC) classification system 50
 Animal and Plant Health Inspection Service (APHIS) 39, 163
 annual safety report 98
 anti-HIV drug target 52
 apixaban 81, 82
 asthma 60
 Asthma inhaler 20
 audit findings and consequences 286–289
 automatic identification and data capture (AIDC) 237
 AZT (zidovudine) 52

b

bar-code 237
 Barium 48

binding assays 58
 bioavailability 73–74, 82, 113, 158, 179, 181, 182
 biologics license application (BLA) 110, 135
 Biologics Price Competition and Innovation Act (BPCI Act) 185
 biopharmaceutical products 61, 63, 73, 78, 183
 biosimilars
 EU regulations 184, 185
 US regulations 185–189
 biotech products/biopharmaceuticals 135
 breath test 20, 48

c

carcinogenicity tests 76, 143
 case report forms (CRFs) 97, 117
 Center for Biologics Research and Evaluation (CBER) 102
 Center for Drug Evaluation and Research (CDER) 36, 102
 Center for Veterinary Biologics (CVB) 39, 146, 158, 163
 Center for Veterinary Medicine (CVM) 39, 146, 158
 chemical substances 58
 chemotherapy drugs 2

- cleaning validation 266–267
- clinical evaluation plan 221, 222
- clinical performance study plan (CPSP) 225, 226
- clinical trial authorisation 95
- clinical trials
 - definition 85
 - design 88–90
 - good clinical practice 90
 - in EU
 - adverse event reporting 97
 - amendments 97
 - annual safety report 98
 - authorisation 95
 - case report forms 97
 - end of trial 98
 - ICH efficacy guidelines 92
 - Independent Ethic Committees 96, 97
 - informed consent 94
 - investigational medicinal product dossier 94
 - investigational medicinal products 95
 - investigator 94
 - Investigator’s Brochure 93
 - monitoring of trials 98
 - protocol 94
 - sponsor 93
 - trial master file 98–100
 - phase I trials 86
 - phase II trials 86–87
 - phase III trials 87
 - process 87
 - in US
 - clinical trial information 105
 - communication with FDA 104
 - federal regulations 100, 101
 - Institutional Review Board 103–104
 - investigational drugs 105
 - Investigational New Drug Applications 100–103
- Clinical Trials Information System (CTIS) 92
- Code of Federal Regulations (CFR) 4, 15, 16, 101, 163, 247, 250, 263, 268
- combination product 191–192
- Committee for Advanced Therapies (CAT) 32, 129
- Committee for Medicinal Products for Human Use (CHMP) 31, 128–130
- Committee for Orphan Medicinal Products (COMP) 166
- Common European Submission Portal (CESP) 133
- common specifications (CS) 222, 235
- common technical document (CTD) 109
 - clinical study reports 116–118
 - Drug Master File 116
 - EU 121–123
 - module structure 112
 - non-clinical study reports 116
 - quality 113–115
 - quality overall summary 120
 - region specific 120
 - structure and hierarchy 110, 111
 - US 123–127
- competent authorities 30, 32–34, 95, 98, 112, 121, 128, 129, 132, 133, 138, 145, 146, 156, 178, 179, 231, 236, 238, 243, 276–278, 280, 288, 290, 292–295, 298, 299
- competitive inhibitors 54, 71
- Complete Response Letter 137
- computer systems validation 262–265
- computerised topography (CT) scans 48

- confirmatory trials 88, 89, 174
- conformity assessment procedures
232–233
- EU (self) declaration of conformity
236
- EU type-examination 235
- EU verification 235–236
- production quality assurance
certification 235
- quality management system
233–235
- technical documentation 233–235
- coordination group for mutual
recognition and decentralized
procedures–human (CMDh)
132
- corrections/removals of devices 300
- Council Directive 90/385/EEC 12
- Council of the European Union 4
- COVID-19 pandemic 2, 53
- COVID vaccines 53, 174
- crossover trial designs 89
- Cryo-Electron Microscopy 58
- current Good Manufacturing Practice
(cGMP) 248
- cytochrome P450 enzymes 73
- d**
- decentralised marketing
authorisation process 133
- decentralised or mutual recognition
procedures 128, 132–133,
182
- decision making process 130, 131,
300
- de novo 510(k) notification procedure
240
- design changes 218
- design input 214–218
- design qualification (DQ) 261
- design review 214, 217, 218
- design validation 216–218
- design verification 216, 217
- Device Master Record (DMR) 268
- diagnostic drugs 20, 48
- Diagnostics Directive 98/79/EC Two
new Regulations 12
- Directive 2001/82/EC 7–9, 11, 110
- Directives/Regulations 5, 6
- DNA nucleotide thymidine 52
- DNA sequence 52, 78
- documentation 25–27, 80, 96, 99,
112, 134, 157, 224, 225, 229,
233–237, 249, 257–259, 278,
280, 281
- drug approval 81, 85, 175, 180,
296
- drug authorisation 8, 165–194
- drug binding interactions 49
- drug categorisation
drug discovery 51
lead discovery, validation and
optimization 57, 58
mode of action 48, 49
physical properties 48
prescription status 47, 48
target discovery and validation
52–57
therapeutic use 49, 50
- drug delivery
drug characteristics 60, 61
location 60
speed and duration of 62–63
stability 63
- drug development 58–59, 63, 65, 77,
80, 93, 105, 140, 167
- drug discovery 47–63, 77
- Drug Master File 116, 124
- drug products 2, 19, 20, 38, 47, 53,
62, 63, 65, 72, 73, 78, 87, 95, 113,
115, 116, 139, 146, 159, 165,
177, 179, 180, 182, 245–248,
259
- drugs and medical devices 1, 15

e

economic operators and devices 238
 510(k) pre-market notification
 process 239
 electronic common technical
 document (eCTD) 109, 111
 electronic signatures 26, 121, 263
 Eliquis 81
 EMA's Paediatric committee (PDCO)
 32, 170
 emergency use authorization (EUA)
 174, 175
 emgality 105, 106
 end of trial 98
 Enterprise Resource Planning (ERP)
 systems 263
 enzyme supplements 20
 essential documents 98, 99
 eSubmission Gateway 121, 129
 EUDAMED 30, 224, 225, 238, 278,
 298, 299
 EU (self) declaration of conformity
 236
 EudraVigilance database 97, 292,
 293
 EudraVigilance IT system 290–293
 EU legislation 5, 7–12, 15, 29, 35, 78,
 176
 EU legislative process 4–6
 EU Marketing Authorisation
 Application form 122
 EU regulations 5, 7, 30, 110, 122,
 177, 181–182, 184–185, 218,
 231, 276
 European Commission 4, 29–31,
 132, 152, 157, 158, 167, 177,
 178, 200, 224, 280, 290, 294

European Economic Area (EEA)
 agreement 130
 European GMP regulations 247, 281
 European legislation Regulation (EC)
 No 1924/2006 19
 European Medicines Agency (EMA)
 30–32, 170, 171, 276
 European Norms (EN) 200
 European Parliament 4, 5, 7, 31, 91
 European Pharmacopoeia (Ph.Eur)
 7, 39, 40, 77, 192
 European Public Assessment Report
 (EPAR) 81, 106, 130, 137
 European Union (EU) 1, 4, 30, 31,
 39, 44, 92, 110, 132, 147, 149,
 156, 170, 175, 208, 246, 247, 290
 EU type-examination 235
 EU verification 235, 236
 Expression proteomics 56
 Extensible Markup Language (XML)
 112

f

factorial trial design 90
 FDA Adverse Event Reporting System
 (FAERS) 296
 FDA MedWatch system 296
 Federal Food, Drug, and Cosmetic
 Act (FDC Act) 12, 36, 210,
 211, 246, 288
 Field Safety Corrective Action (FSCA)
 298, 299
 Food and Drug Administration (FDA)
 12, 35, 36, 39, 105, 146, 278
 Food Safety and Inspection Service
 (FSIS) 159

g

Generally Recognised as Safe and
 Effective (GRASE) 193
 generic drugs
 definition 181

- EU Regulations 181, 182
 - US Regulations 182
 - genetic engineering 48, 135, 183
 - genome 55, 56
 - genome sequencing 56
 - Good Automated Manufacturing Practice (GAMP) 263
 - good clinical practice (GCP) 25, 90, 91, 141–146, 222
 - good manufacturing practice (GMP) 95
 - essential requirements
 - complaints 259
 - documentation 257, 258
 - emergency un-blinding 259
 - personal hygiene 248–249
 - premises and equipment 249–257
 - production 257–258
 - quality assurance system 248, 254
 - quality control 258, 259
 - recall product 259
 - self-inspection 259, 260
 - work contracted out 259
 - regulations and guidance 245–247, 252
 - requirements 268, 272
 - validation
 - cleaning 266, 267
 - computer systems 262–265
 - facilities and equipment validation 261
 - methods 265–266
 - process capability 261, 262
 - process validation 262
 - sterilisation procedures 267, 268
 - typical system 260, 261
 - water purification systems 268
 - good pharmacovigilance practice (GVP) 290, 291
 - guidance documents 7, 29, 30, 36, 41, 42, 44, 69, 90, 112, 211, 281, 291
- h**
- HAZOP analysis 262
 - health foods 19
 - Health Level Seven Individual Case Safety Reporting system (HL₇ICSR) 300
 - heating, ventilation and air conditioning (HVAC) systems 249
 - hepatitis B 53
 - high-efficiency particulate air (HEPA) filters 255
 - homeopathic medicines 192
 - homeopathic remedies 19
 - hormone replacement therapy 48
 - human factor Xa 81, 82
 - Human Immunodeficiency Virus (HIV) 52
 - human medicines 8, 9, 33, 34, 47, 139, 140, 156, 157, 181, 190, 191, 289, 290, 294, 296
 - human prescription drugs 48
 - Humanitarian Device Exemption (HDE) application 243
 - humanitarian use device (HUD) 243
- i**
- ICH Q5 guidelines 78
 - Independent Ethic Committees 96
 - informed consent 94, 96, 145, 223, 225, 227
 - inspection
 - audit findings and consequences 286–289
 - techniques 280–286
 - installation qualification (IQ) 27, 261

Institutional Review Board (IRB)
103–104, 145, 227

International Electrotechnical
Commission (IEC) 200

International Harmonisation Bodies
40–41

International Medical Device
Regulators forum (IMDRF)
43, 44, 280

International Standards Organisation
(ISO) 200

Investigational Medicinal Product
Dossier (IMPD) 94

investigational medicinal products
85, 91, 93–95, 98, 246, 293

Investigational New Drug
Applications (INDs) 100–103,
174

investigator 89, 93–98, 101, 104, 124,
145, 147, 223, 229

Investigator’s Brochure (IB) 93, 223

in vitro models 73

in vitro tests 75, 76

in vivo animal studies 73

in vivo bioavailability studies 74

j

Joint Expert Committee on Food
Additives (JECFA) 148

judicial branch function 4

l

labelling requirements 124,
236–238, 241, 243

licensing requirements, additional
279

m

magnetic resonance imaging (MRI)
48

manufacturing authorisation of
medicinal products in the EU

documented information 276

registration of economic operators
for medical devices 278

wholesale distribution of medicinal
products 276–277

marketing authorization 156

common technical document
clinical study report 116–118

Drug Master File 116

EU 121–123

module structure 112

non-clinical study report 116

quality 113–115

quality overall summary 120

region specific 120

structure and hierarchy 110,
111

US 123–127

submission and review process, in
EU

decentralised procedure 132,
133

decision making process
130–132

mutual recognition procedure
134

national authorisations 132

plasma master files and vaccine
antigen master files 134

scientific evaluation process
129, 130

union authorisation 128–129

submission and review process, in
US 134–137

market vigilance 23, 24, 34, 275,
289–303

market vigilance & oversight of drugs
EudraVigilance IT system 290

market vigilance in the EU 298

periodic reports 296–297

- pharmacovigilance and marketing
 - authorization holders 293–294
- pharmacovigilance and reporting in
 - US 295–296
- pharmacovigilance in EU 289–290
- pharmacovigilance inspections and audits 294–295
- Pharmacovigilance Risk Assessment Committee (PRAC) 290–293
- renewal of marketing authorisations 295
- mass spectrometry (MS) 56
- Master Production and Control Record 257, 268
- maximum residue limits (MRLs) 29, 139, 147–149, 154
- Measles 2
- medical conditions 19, 52, 53
- Medical Device Coordination Group (MDCG) 30, 201, 231
- medical device reporting 299–300
- Medical Device Single Audit Program (MDSAP) 44, 280
- medical device vigilance in the US 299
- medical devices
 - development of drugs and devices
 - design & development planning 214
 - design changes 218
 - design controls 213–214
 - design input 214–216
 - design output 216
 - design review 217
 - design validation 216–217
 - design verification 216–217
 - risk analysis 218
 - in EU
 - conformity assessment
 - procedures 232–236
 - economic operators and devices 238
 - labelling requirements 236–238
 - Notified Bodies 230–232
 - production quality assurance
 - certification 235
 - requirements *versus* risk 244
 - technical documentation 236, 237
 - in Europe
 - clinical evaluation 221, 222
 - clinical investigations 222–225
 - performance evaluation of IVDs 225
 - performance studies of IVDs 225, 226
 - regulatory strategy, EU
 - classification 201–210
 - MDR *vs.* IVDR 196–199
 - standards 200–201
 - regulatory strategy, US 210–212
 - in US
 - abbreviated 510(k) 239
 - abbreviated requirement investigations 227
 - de novo 510(k) notification
 - procedure 240
 - exempted investigations 227
 - 510(k) pre-market notification
 - process 239
 - humanitarian use device 243
 - IDE investigations 227–231
 - labelling devices 229, 243
 - notification and review
 - procedures 240
 - PMA-approved device 241–243
 - pre-market approval 240, 241
 - requirements *versus* risk 244
 - special 510(k) procedure 239–240

- medical devices (*contd.*)
 - traditional 510(k) notifications 239
- Medical Devices Directive 93/42/EEC 12
- Member States concerned 95, 97
- methods validation 113, 265–266
- Minor Use and Minor Species (MUMS) amendments 176
- monitoring of trials 98
- Mumps 2
- mutual recognition procedure 128, 132, 134, 182

- n**
- National Authorisations 127, 132, 178
- National Committee for Clinical Laboratory Standards (NCCLS) 200
- national legislation 5, 6, 133
- New Animal Drug Application (NADA) 158–162, 182
- New Drug Application (NDA) 110, 123, 135, 136, 193
- nexviazyme (avalglucosidase alfa-ngpt) 137
- NMR spectroscopy 58
- non-clinical study
 - bioavailability and bioequivalence 73, 74
 - carcinogenicity studies 76
 - chemistry, manufacturing and control development (CMC) 77
 - clinical trial and marketing authorisation phases 66
 - genotoxicity studies 75, 76
 - good laboratory practice (GLP) 78–80
 - ICH harmonised safety and quality guidelines 67
 - pharmacological studies 69–71
 - pre-clinical phase of drug development 65
 - quality by design (QbD) 77
 - reproductive toxicology studies 76, 77
 - safety and preliminary efficacy indications 65
 - stability studies 78
 - toxicity studies 74, 75
- non-polar drug 60, 72
- notification and review procedures 240
- Notified Bodies 31, 34–35, 44, 80, 195, 199, 201, 224, 230–233, 235–238, 240, 243, 278, 280, 298

- o**
- Office of Orphan Products Development (OOPD) 166
- Omeprazole 54, 55
- open-label trial 89
- operational qualification (OQ) 27, 261
- Organisation for Economic Cooperation and Development (OECD) 78
- orphan drugs 12, 13, 165–168, 190, 193, 243
- over-the-counter (OTC) 40, 47, 48, 191, 193, 259
- OvuGel 157, 158

- p**
- paediatric investigation plans (PIPs) 92, 170
- paediatric legislation 170
- patented medicines 59
- peptic ulcers 53

- performance qualification (PQ) 27, 261
 - Periodic Adverse Drug Experience Reports (PADERS) 296
 - periodic reports 243, 296–297
 - periodic safety update reports (PSURs) 236, 294
 - personal hygiene 248
 - pest control programme 251
 - Pharmaceutical Inspection Cooperation Scheme (PICS) 44, 45, 276, 281
 - pharmaceutical manufacture, in Europe 247
 - pharmacological studies
 - pharmacodynamic studies 70, 71
 - pharmacokinetic/toxicokinetic studies 72, 73
 - pharmacovigilance and marketing
 - authorisation holders 293, 294
 - pharmacovigilance & reporting, in US 295, 296
 - pharmacovigilance, defined 289
 - pharmacovigilance inspections and audits 294, 295
 - Pharmacovigilance Risk Assessment Committee (PRAC) 32, 128, 290–293
 - pharmacovigilance systems, in Europe 289
 - photostability 78
 - Plan-Do-Check-Act (PDCA) 201
 - plasma master files & vaccine antigen master files 134
 - Portable Document Format (PDF) files 112
 - post-authorisation safety studies (PASS) 290, 293
 - post-market clinical follow-up (PMCF) data 221, 303
 - post-market surveillance 222, 224, 236, 278, 298, 299, 302–303
 - pre-market approval process (PMA) 240, 241
 - prescription-only medicines (POM) 47
 - process validation 113, 115, 262, 273
 - processing changes
 - in EU
 - extension applications 178
 - major variation (type II) 178, 179
 - minor variation (type IA/IB) 179
 - in US
 - major changes 180
 - manufacturing change supplements 180
 - minor changes 181
 - moderate changes 180, 181
 - product development 23, 175, 212
 - production quality assurance
 - certification 235
 - product manufacture 23, 24, 262
 - product safety 1, 287
 - proton pump inhibitors 54, 55
 - Public Health Services (PHS) Act 15
- q**
- quality assurance system 25, 248, 254
 - quality by design (QbD) 77
 - quality control 59, 93, 214, 249, 251, 257–259, 276, 281
 - quality management system 201, 202, 213, 233–235, 268, 273, 294, 298
 - quality management system
 - regulation (QMSR) 213, 268
 - Quality System Inspection Technique (QSIT) 286

- Quality System Regulation (QSR)
 - 211, 213, 268, 270, 280, 287
- quantitative proteomics approach
 - 57
- r**
- radio frequency identification (RFID)
 - 237
- reference drug exclusivity 189–191
- registration of economic operators
 - 238, 278
- registration of manufacturers 275, 303
- registration of producers of drugs and devices in the US 278, 279
- Regulation (EC) No. 726/2004 7, 9, 170, 176, 290
- Regulation (EU) 2019/6 7, 8, 145, 156, 177, 181, 246, 275, 290
- Regulations
 - EU Legislation 7–12
 - EU Legislative Process 4–6
 - guidance documents 7
 - legal texts 6
 - National Legislative Process 3, 4
 - pharmacopoeial publications 7
 - principles and concepts 1
 - product safety 1
 - scope of legislation 15–20
 - US Legislation 12–15
- Regulatory strategy
 - EMA 30–32
 - European Commission 29, 30
 - Food and Drug Administration (FDA) 35–39
 - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 41–43
 - International Harmonisation Bodies 40–41
 - International Medical Device Regulators forum (IMDRF) 43, 44
 - market vigilance 24
 - national competent authorities 32–34
 - notified bodies 34, 35
 - Pharmaceutical Inspection Cooperation Scheme (PICS) 44, 45
 - pharmacopoeia authorities 39, 40
 - product development 23
 - product manufacture 23
 - quality assurance systems 25
 - quality assurance systems
 - corrective and preventative action 27
 - documentation 25, 26
 - facilities and equipment 26, 27
 - personnel 25
 - US Department of Agriculture 39
 - validation 27, 28
 - veterinary medicinal products (VICH) 43
 - World Health Organisation (WHO) 45
- relative polarity 60
- renewal of marketing authorisations 295
- retrospective validation 262
- rheumatoid arthritis (RA) 53
- risk analysis 215, 218, 230, 240, 260, 263, 264, 268, 269
- Risk Evaluation and Mitigation Strategy (REMS system) 296
- Rubella 2
- Rules Governing Medicinal Products 30, 92, 110, 149, 156, 246, 247
- S**
- scientific evaluation process 129, 130

- single registration number (SRN)
 - 238, 278
 - special 510(k) procedure 239, 240
 - special drug applications
 - accelerated access to new drug therapies
 - emergency use authorization 174, 175
 - EMA accelerated review and conditional marketing routes 170, 171
 - EU compassionate use 171
 - expanded access 174, 175
 - expedited pathways, in US 171–174
 - orphan drugs 165–168
 - paediatric applications 167–170
 - statistical power 89
 - Stents 20
 - sterilisation procedures 242, 267, 268
 - structural proteomics 56, 58
 - submission and review process
 - in EU
 - decentralised procedure 132, 133
 - decision making process 130–132
 - mutual recognition procedure 134
 - national authorisations 132
 - plasma master files & vaccine antigen master files 134
 - scientific evaluation process 129, 130
 - union authorisation 128, 129
 - in US 134–137
 - summary basis of approval (SBC)
 - document 137
 - summary of product characteristics (SPC) 94, 122, 123, 129, 134, 156, 178
 - Suspected Unexpected Serious Adverse Reactions (SUSAR's) 97, 293
- t**
- target validation 57
 - technical documentation 233–237, 278
 - therapeutic categories 49, 50
 - traditional fine-chemical-based pharmaceutical products *versus* biopharmaceuticals 184
 - traditional 510(k) notifications 239
 - traditional herbal medicines 19, 192, 193
 - Trial Master File 98, 99
 - tumour necrosis factor-alpha (TNF- α) 53, 57
- u**
- ultrasound 20, 227
 - union authorisations 127–129, 132, 156, 179
 - union marketing authorisation process 130, 131
 - unique device identifier (UDI) 199, 237
 - United States Code (USC) 12
 - United States Pharmacopoeia (USP) 7, 256, 257
 - US Legislation 12–15
- v**
- vaccination 2, 53, 156
 - Vaccine Adverse Event Reporting System (VAERS) 296
 - vaccine technology 53
 - verquvo (vericiguat) 132
 - veterinary biologics licence applications 158
 - Veterinary Feed Directive (VFD) drug 159

- veterinary good pharmacovigilance practice (VGVP) guideline 290
 - veterinary medicinal products (VICH) 7, 29, 30, 43, 139, 146, 149, 156, 164, 177, 178, 246, 275
 - veterinary medicines
 - clinical trials
 - in EU 145–146
 - in US 146, 147
 - development process
 - clinical trials 141
 - Good Clinical Practices 141–145
 - pre-clinical studies 140, 141
 - in EU
 - establishment of MRLs 149–152
 - marketing authorisations 156
 - MRL applications 150–152
 - MRL dossier 153
 - technical dossier 156, 157
 - maximum residue limits 147–149
 - in US
 - New Animal Drug Application 158–162
 - veterinary biological products 163–164
 - Virus-Serum-Toxin Act 15, 163
- W**
- water purification system 256, 268
 - well-established medical use products 191
 - wholesale distribution of medicinal products 276, 277
 - work contracted out 259
 - Working Groups (WG) 30, 41, 44
 - World Health Organisation (UN WHO) 41, 45, 50, 148, 171
- X**
- X-ray crystallography 58
 - X-ray equipment 20, 36

